Recon: FDA approves Supernus ADHD drug Qelbree; Valneva to begin Phase 3 trial of its COVID vaccine

• Moderna Vaccine Production Pace to Increase at CMO Catalent (WSJ) (Endpoints)
• Walgreens Not Following US Guidance on Pfizer Vaccine Spacing (NYTimes)
• Biden Tax Plan Seen Hitting Tech, Pharmaceutical Companies (Bloomberg)
• Biden to speed up eligibility for vaccine as US hits milestone (Reuters)
• Former USAID chief tapped to lead vaccine diplomacy efforts (Politico) (Reuters)
• White House says monitoring coronavirus vaccine distribution in Florida (Reuters)
• Novavax starts allowing participants on placebo to get COVID-19 vaccine in trials (Reuters)
• FDA OKs first new ADHD drug in over a decade for children (AP) (Axios)

• EMA Official Links AstraZeneca Vaccine And Thrombosis (AFP) (Reuters)
• Europe medicines watchdog to update on AstraZeneca vaccine safety April 7 or 8 (Reuters)
• EU denies blocking 3.1 million AstraZeneca shots to Australia (Reuters)
• EU blames AstraZeneca 'failure' as it misses vaccination target (The Guardian)
• EU expects to vaccinate majority by end-June – Bloomberg (Reuters)
• UK health regulator may restrict AstraZeneca shot for younger people, Channel 4 says (Reuters) (The Guardian)
• South Korea flags possible vaccine export curbs to secure COVID-19 shots (Reuters)
• Valneva's COVID-19 shot set for Phase Three trial this month (Reuters) (FT)

• Global COVID-19 death toll surpasses 3 million amid new infections resurgence (Reuters)
• The Story of One Dose: Inside the sprawling operational puzzle of bringing the Johnson & Johnson COVID vaccine to the public. (NYMag)
• New IMF reserves could fund vaccinations for low-, middle-income countries -report (Reuters)
• South Africa signs deal for 20 million Pfizer vaccine doses (Reuters)
• Ortho signs $53.7M government contract to triple its COVID-19 test production (Fierce)

• Drug prices: the lucrative world of not-so-cheap imitations (FT)
• Furious Acadia takes shot at FDA, alleging sudden about-face in costly Nuplazid rejection (Fierce)
• FDA Neuroscience Director Dunn's Appearance At Tanezumab AdComm Confirms Neurology Office Is Intact (Pink Sheet)
• New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds (BioPharmaDive)
• Alexion Secures Funding OK In England For GI Bleeding But Wants More (Pink Sheet) (PharmaTimes)
• EC approval for Ontozry (PharmaTimes)
• AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large (Endpoints)
• Alnylam publish successful results from Phase III study of ultra-rare disease (Pharmafile)
• Janssen agrees $780 million deal for authorisation of Cidara flu treatment (Pharmafile)
• Amarin launches Vascepa in all-important Europe as it slowly bleeds share to US generic (Fierce)
• Pharma Companies Need To ‘Think A Little Bigger’ To Avoid Government Enforcement Actions (Pink Sheet)
• Lilly is a holdout among companies that agree to disclose when executive pay is clawed back (STAT)
• In 1-2 punch, Molecular Templates cuts first-gen candidate and loses a Big Pharma partner; Charles River teams up with Valence to provide AI discovery platform (Endpoints)
• 'Unsurprising' but 'deeply disappointing': Deerfield report finds vast gender gap in VC-backed healthcare (Fierce)
• After Novartis walks on last STING drug, Chinook spits out orphan Aduro assets (Endpoints)
• Mineralys emerges with a new take on an old idea for the treatment of hypertension and $40M to play with (Endpoints)
• With fresh investor cash in hand, Volastra partners with Microsoft to develop metastatic cancer biomarker platform (Endpoints)
• Big Pharma R&D veteran with blockbuster credentials returns to his biotech roots as Prothena's new CMO (Endpoints)
• The 20(+1) under 40: Inside the next generation of biotech leaders (Endpoints)

• UK Medtechs Say Conditional Reimbursement Will Open Doors To Innovation Adoption (MedtechInsight)
• Dexcom G6 Sensor: untested barrier methods to reduce skin reactions (MHRA)
• Dexcom links with Welldoc to chart a digital path for its CGM into Type 2 diabetes (Fierce)
• MHLW Launches New Office to Fuel SaMD Commercialization (PharmaJapan)

• Pharmacies Can't Escape More Trials In Opioid MDL (Law360)
• Justices Won't Revive Teva-IBSA Thyroid Drug Patent Fight (Law360)
• 9th Circ. Revives Claims That Medtronic Skirted FDA Review (Law360)
• First Circuit Closes Front and Back Door on Massachusetts Pharmacy Liability Case (Drug & Device Law)
• Teva, Pharmacies Want Humana's Copay Fraud Claims Tossed (Law360)
• CVS Wants Tribe To Arbitrate Prescription Reimbursement Suit (Law360)
• Illumina Wants FTC's Suit Over $8B Grail Deal Moved To Calif. (Law360)